Vitrolife Group
Vitrolife Group is a Swedish-listed global provider of IVF medical devices, consumables, and reproductive genetic testing. Through its Vitrolife and Igenomix brands, it serves IVF clinics and reproductive-health professionals in over 25 countries with consumables, the EmbryoScope/iDAScore AI embryo-evaluation platform, and genetic tests such as ERA and non-invasive PGT.
- Company typePublic
- Founded2001
- HeadquartersVästra Frölunda, Sweden
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Vitrolife Group does
Vitrolife Group (Vitrolife AB (publ)) is a Swedish-headquartered, NASDAQ Stockholm Large Cap-listed provider of medical devices, consumables, and genetic testing services for the global IVF market. Operating through two main brands — Vitrolife (consumables and technologies) and Igenomix (reproductive genetic testing) — the group sells oocyte retrieval needles, cryopreservation devices, transfer media, the EmbryoScope time-lapse incubation system with the proprietary iDAScore AI embryo-evaluation model, laser technology, and the eWitness/eBase clinic management software acquired with eFertility in May 2024. Igenomix contributes a portfolio of reproductive genetic tests including the pioneering Endometrial Receptivity Analysis (ERA), PGT, and a non-invasive PGT approach using cell-free DNA in embryo culture medium.
The group serves IVF clinics and reproductive-health professionals (clinicians, embryologists, genetic counsellors) in more than 25 countries, with priority growth markets in the US, Europe, Japan and Asia-Pacific. Revenue is generated through three streams: medical device and consumables sales to IVF clinics (hardware/consumables revenue), genetic testing services via Igenomix (professional services revenue), and increasingly software/SaaS-style digital clinic management through eWitness/eBase (subscription/recurring revenue). Pricing is quote-based through a direct global sales force with regional SVP/MD leadership, supported by the Vitrolife Group Academy for clinician training and enablement, and brand-dedicated websites (vitrolife.com and igenomix.eu). The company employs around 1,150 colleagues and is incorporated in Gothenburg, Sweden under Vitrolife Aktiebolag (publ), with Igenomix (Spain) and eFertility as wholly-owned operating subsidiaries.
Recent strategic posture is defensive and consolidating. A December 2025 genetic services restructuring (targeting SEK 65M annualised savings, discontinuing two test lines and exiting low-profit markets) accompanied a SEK 5.4 billion goodwill impairment related to the Igenomix acquisition in Q4 2025. The CEO Bronwyn Brophy O'Connor announced her departure on 22 May 2026, while a new COO (Olivier Desmarets) was appointed 1 June 2026 to lead global Manufacturing, Labs, Supply Chain, Quality and Customer Care. The company is listed (ticker VITR; ISIN SE0011205202) with major shareholders including William Demant Invest A/S, Bure Equity AB, and AMF Fonder & Pension represented on the Nomination Committee.
Vitrolife Group firmographics
Firmographics- Name
- Vitrolife Group
- Legal name
- Vitrolife Aktiebolag (publ)
- Website
- https://vitrolifegroup.com
- Company type
- Public
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Vitrolife Group is a Swedish-listed global provider of IVF medical devices, consumables, and reproductive genetic testing. Through its Vitrolife and Igenomix brands, it serves IVF clinics and reproductive-health professionals in over 25 countries with consumables, the EmbryoScope/iDAScore AI embryo-evaluation platform, and genetic tests such as ERA and non-invasive PGT.
- Ownership category
- akta.pro rank
Vitrolife Group industry classification
Industry- Product category
- Reproductive Health Medical Devices & Genetic Testing
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Reproductive Endocrinology & Infertility (IVF/Fertility) (HLAKAJAC)
- akta.pro secondary industries
- Fertility, Reproductive Endocrinology & IVF Centers (HLAFAJAD), Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN)
Keywords
Where Vitrolife Group is headquartered
LocationHeadquarters
- HQ city
- Västra Frölunda
- HQ country
- Sweden
- HQ region
- Europe
Offices3 records
Markets served
Vitrolife Group business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Medical device and consumables sales: Sale of Vitrolife-branded IVF consumables (oocyte retrieval needles, cryopreservation devices, transfer media) and Technologies (time-lapse systems, laser, witnessing) to IVF clinics globally.
- Genetic testing services: Sale of Igenomix genetic tests (e.g., ERA, PGT-A, non-invasive PGT) to reproductive-health professionals across the reproductive journey.
- IVF clinic management software (eWitness / eBase): Software/SaaS-style digital clinic management and electronic witnessing for IVF workflows, acquired via eFertility (EUR 1.5 million revenue in 2023).
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Vitrolife Group product offering
Product offeringCore offering
Vitrolife Group is a global provider of medical devices, technologies, and genetic testing solutions for the IVF and reproductive-health journey. Its portfolio spans Consumables (oocyte retrieval needles, cryopreservation devices, transfer media), Technologies (EmbryoScope time-lapse incubation, laser technology, AI-based embryo evaluation via iDAScore, eWitness witnessing systems), and Genetic Services delivered under the Igenomix brand (Endometrial Receptivity Analysis, PGT, non-invasive PGT via cell-free DNA). It also sells IVF clinic management software (eBase) acquired via eFertility.
Product overview
Vitrolife Group operates a platform-plus-modules architecture organized under two primary brands: Vitrolife (medical devices and clinic software for IVF) and Igenomix (genetic testing services for reproductive health). The Vitrolife brand is structured into Consumables (oocyte retrieval needles, cryopreservation devices, transfer media), Technologies (the EmbryoScope time-lapse system, laser technology, and the witnessing system eWitness acquired via eFertility), and the broader IVF workflow suite that includes the eBase clinic management platform. Igenomix provides the genetic services portfolio (including the ERA endometrial receptivity analysis) covering pre-, during-, and post-reproductive stages. AI capability is delivered through the in-house iDAScore model that sits on top of EmbryoScope time-lapse imagery, and the group has expanded into adjacent automated IVF technology via its investment in AutoIVF and its OvaReady product.
Differentiator
Problem solved
Functional benefit
Brands
- Vitrolife: Brand of innovative, high-quality IVF journey products including oocyte retrieval needles, cryopreservation devices, transfer media, pioneering time-lapse and laser technology, and the latest witnessing system.
- Igenomix
Products and services
- Vitrolife Consumables
Quantifiable outcome
- 5% organic growth in local currencies in Q1 2026 with strong growth in Consumables and Technologies
- +2 more outcomes
Companies that use Vitrolife Group
Customer profileSegments3 records
Ideal customer profiles2 records
Vitrolife Group technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature5 records
Vitrolife Group partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered major / strategic acquisition target, transformational acquisition, operational / compliance, statutory auditor (high importance for governance), key opinion leader / scientific partner, key opinion leader in japan, key opinion leader / clinic chain partner and key opinion leader in the us.
- eFertilitymajor / strategic acquisition targetVitrolife signed an agreement to acquire all shares of eFertility for EUR 9.6 million plus potential earn-out, completed on 22 May 2024. The deal brought eFertility's eWitness and eBase IVF clinic management systems into Vitrolife Group, supporting its strategy to digitalise and standardise IVF workflows worldwide. eFertility contributed EUR 1.5 million in revenues in 2023.
- Igenomix S.L. (acquired via Mendel Holdco S.L.)transformational acquisitionVitrolife acquired all shares in Mendel Holdco S.L. and thereby indirectly all shares in Igenomix S.L. in 2021 via a directed share issue, increasing share count by 17,251,312 (12.7% dilution) and share capital by SEK 3,519,267.648. Igenomix is now a core brand within Vitrolife Group's Genetic Services portfolio.
- WhistleB / NAVEX (whistleblowing service provider)operational / complianceExternal partner providing Vitrolife Group's anonymous and encrypted whistleblowing service (report.whistleb.com/en/vitrolife), administered by WhistleB Whistleblowing Centre AB (Stockholm). Handles criminal offences, financial irregularities, health & safety, environmental and privacy violations.
- Deloitte ABstatutory auditor (high importance for governance)Deloitte AB was re-elected at the 2026 AGM as Vitrolife's statutory auditor for one year, with Anneli Pihl (authorised public accountant) as auditor in charge. Office: Södra Hamngatan 53, Box 33, SE-401 20 Göteborg.
- Melbourne IVF / Virtus Health (David K. Gardner)key opinion leader / scientific partnerScientific collaboration with David K. Gardner, Scientific Director of Melbourne IVF, a pioneer of blastocyst culture and the 'Gardner Grade' embryo grading system. He contributed to the Capital Markets Day 2023 on IVF history and future.
- Kato Ladies Clinic (Keiichi Kato, M.D.)key opinion leader in japanClinical perspective partner; Dr. Keiichi Kato, General Director of Kato Ladies Clinic (Tokyo), participates in Vitrolife's CMD 2023 panel on IVF market dynamics in Japan and natural/minimal stimulation IVF.
- Eugin Group (Eduardo Gonzalez)key opinion leader / clinic chain partnerClinical perspective partner; Eduardo Gonzalez, Group CEO of Eugin Group (a reproductive-health clinic chain headquartered in Barcelona, Spain), contributes to the CMD 2023 panel on European IVF market dynamics.
- UCSF Center for Reproductive Health (Mitchell Rosen, M.D.)key opinion leader in the usClinical perspective partner; Dr. Mitchell Rosen of UCSF participates in CMD 2023 panels on IVF market dynamics and clinical experience using EmbryoScope.
Scale indicators8 records
Recent moves8 records
Expansion highlights6 records
Vitrolife Group competitors and assessment
Company assessmentDirect peers
- FUJIFILM Irvine Scientific: A leading global supplier of IVF culture media, cryopreservation solutions, and ART devices, directly competing with Vitrolife's Consumables portfolio. Its media franchise is the closest substitute to Vitrolife's transfer media and cryopreservation products used by the same IVF clinics.
- Natera: Natera's Spectrum PGT-A and Empower hereditary cancer test compete head-on with Igenomix's PGT-A and reproductive genetics offering. Both target the same IVF-clinic channel for preimplantation and reproductive genetic testing decisions.
- Kitazato Corporation: Kitazato is a leading Japanese provider of IVF consumables, cryopreservation devices (Cryotop), and culture media, competing directly with Vitrolife Consumables across Asia-Pacific and globally, particularly in Japan - one of Vitrolife's stated priority markets.
- Genea Biomedx: Genea Biomedx (part of Genea World) supplies IVF lab equipment including the Geri time-lapse incubator and Gems culture media, directly competing with Vitrolife's EmbryoScope time-lapse system and Consumables media range. Both target the same IVF lab purchasing decision.
- Hamilton Thorne: Hamilton Thorne manufactures time-lapse embryo incubators (e.g., Gery and recently acquired LYKOS) and IVF lab equipment, directly competing with Vitrolife's EmbryoScope and Technologies product lines. Its laser and micromanipulator products further overlap Vitrolife's Technologies portfolio.
- CooperGenomics (Preimplantation Genetics): CooperGenomics provides PGT-A, PGT-M, and PGT-SR genetic testing services to IVF clinics, directly overlapping with Igenomix's PGT portfolio. Both serve the same reproductive-health professional customer with comparable chromosomal and monogenic disease screening tests.
Broad incumbents
- CooperSurgical (CooperCompanies): CooperSurgical's Fertility and Genomic Solutions business directly overlaps with Vitrolife's IVF consumables, genetic testing (PGT-A), and genomics portfolio. As part of a diversified medical-device conglomerate, it competes across multiple layers of the IVF stack but does not match Vitrolife's full end-to-end integration with EmbryoScope/iDAScore.
- Merck KGaA (Life Science / Sigma-Aldrich IVF): Merck supplies IVF/ART media, cryopreservation reagents, and bench research products used by fertility clinics and embryologists, overlapping with Vitrolife Consumables. As a large diversified science conglomerate it competes on breadth rather than Vitrolife's specialty IVF focus.
Regional players
- Progyny: Progyny is a US fertility benefits management company that partners with employers to offer IVF coverage, indirectly influencing demand for Vitrolife's products. While not a direct product competitor, it shapes US purchasing power for the same IVF clinics and could serve as a channel or partnership target for Vitrolife's US push.
Emerging players
- AIVF: AIVF is an Israel-based emerging IVF technology company developing AI-driven embryo evaluation software (EMMA, DALIA), directly competing with Vitrolife's iDAScore AI embryo-scoring model. It represents a focused, well-funded entrant into AI embryo selection that could pressure iDAScore's pricing power.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Vitrolife Group social profiles
Digital presenceVitrolife Group compliance and trust
Trust signalCompliance2 records
Vitrolife Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vitrolife Group leadership team
Management profileNumber of profiles
Profiles19 records
Vitrolife Group subsidiaries and ownership
Company hierarchySubsidiaries2 records
Vitrolife Group funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vitrolife Group M&A and investment
M&A and investmentM&A1 record
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vitrolife Group
What does Vitrolife Group do?
Vitrolife Group is a global provider of medical devices, technologies, and genetic testing solutions for the IVF and reproductive-health journey. Its portfolio spans Consumables (oocyte retrieval needles, cryopreservation devices, transfer media), Technologies (EmbryoScope time-lapse incubation, laser technology, AI-based embryo evaluation via iDAScore, eWitness witnessing systems), and Genetic Services delivered under the Igenomix brand (Endometrial Receptivity Analysis, PGT, non-invasive PGT via cell-free DNA). It also sells IVF clinic management software (eBase) acquired via eFertility.
Is Vitrolife Group a public or private company?
Vitrolife Group is a public company. It is classified as public and is currently operating.
When was Vitrolife Group founded?
Vitrolife Group was founded in 2001. It employs 1,001 to 5,000 people.
Where is Vitrolife Group based?
Vitrolife Group is headquartered in Västra Frölunda, Sweden, in the Europe region.
How does Vitrolife Group make money?
Three revenue lines are on record. Medical device and consumables sales are the primary driver. The others are genetic testing services and IVF clinic management software (eWitness / eBase).
Who are Vitrolife Group's main competitors?
Direct peers on record are FUJIFILM Irvine Scientific, Natera, Kitazato Corporation, Genea Biomedx, Hamilton Thorne and CooperGenomics (Preimplantation Genetics). Broad incumbents are CooperSurgical (CooperCompanies) and Merck KGaA (Life Science / Sigma-Aldrich IVF). Progyny is listed as a regional player. AIVF is listed as an emerging player.
Does Vitrolife Group have an API?
No public API is recorded for Vitrolife Group.
What industry is Vitrolife Group in?
Vitrolife Group's product category is Reproductive Health Medical Devices & Genetic Testing. Its primary akta.pro industry code is HLAKAJAC, Reproductive Endocrinology & Infertility (IVF/Fertility), with a secondary code of HLAFAJAD, Fertility, Reproductive Endocrinology & IVF Centers. Its NAICS code is 325414 and its SIC code is 3841.